Additive Manufacturer Green Trade Association Announces New Members
The Additive Manufacturer Green Trade Association (AMGTA), a global trade organization created to promote the environmental benefits of additive manufacturing (AM), announced today that eight additional leading AM companies have joined the trade group to advance sustainability in AM, bringing its membership ranks to 28 members.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005192/en/
Joining the AMGTA as a new Founding Member is Stratasys, a global leader in polymer 3D printing solutions for industries such as aerospace, automotive, consumer products, and healthcare. Stratasys will serve alongside existing Founding Members ExOne, the pioneer and global leader in industrial 3D printing systems using binder jet 3D printing technology; QC Laboratories, an advanced non-destructive testing laboratory focused on AM components; Sintavia, a designer and 3D printer of a new generation of flight and launch components; and Taiyo Nippon Sanso Corporation (one of the operating companies under Nippon Sanso Holdings Corporation), a supplier of stable industrial gases to a wide variety of global industries. These five Founding Members will determine the strategic direction of the AMGTA, provide governance oversight, and consider future research projects that members may vote to commission.
Joining the AMGTA as new Participating Members are: 3D Metalforge, a global AM company providing greater value to its customer through new and innovative additive manufacturing technologies; 3D Systems, the leader in enabling additive manufacturing solutions for applications in growing markets that demand high-reliability products; 3YOURMIND, an agile manufacturing software solutions provider dedicated to optimizing the additive manufacturing workflow; AMT, a global leader in automated chemical vapor smoothing (post-processing) systems for additively manufactured parts; Hyperion Metals, a Tennessee-focused company developing sustainable, zero carbon titanium metal powders for the growing additive manufacturing industry; NatureWorks, a world-leading biotechnology company using plants to turn greenhouse gases like CO2 into a biopolymer called Ingeo; and The Barnes Global Advisors, the world’s largest independent advanced manufacturing engineering consultancy.
These new Participating Members will serve alongside existing Participating Members AMEXCI, BASF 3D Printing Solutions, Danish AM Hub , DyeMansion, EOS, Fraunhofer Institute for Laser Technology (ILT), GE Additive, HP, Materialise, National Manufacturing Institute Scotland, Rusal America , Siemens Digital Industries Software, SLM Solutions, Stryker, TRUMPF, and 6K.
“I’m elated to welcome aboard our new Founding Member Stratasys, as well as each of our new Participating Member companies,” said Sherry Handel, Executive Director of the AMGTA. “Their collective pledge to support the AMGTA’s mission well-positions our trade group for accelerated growth and investment in new sustainability research projects in additive manufacturing. I look forward to working with each of our members as we expand the AMGTA as the key industry resource committed to advancing sustainability in the AM industry.”
About AMGTA. The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder that meets certain criteria relating to sustainability of production or process.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005192/en/
Contact information
Sherry Handel
+1 954.308.0888
www.amgta.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom